Cat. No. 2197
Chemical Name: 4-[[(Hexylamino)carbonyl]amino]-N-[
Biological ActivityPotent β3-adrenergic receptor partial agonist > 1000-fold selective over β1- and β2-adrenoceptors (EC50 values are 0.43, 580 and > 10000 nM for activation of cloned human β3-, β1- and β2-adrenoceptors respectively). Stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM). Enhances CRISPR-mediated homology-directed repair (HDR) efficiency 2-3-fold for large fragments and ~9-fold for point mutations, in human induced pluripotent stem cells (iPSCs).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Yu et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 142. PMID: 25658371.
Fisher et al (1998) A selective human β3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J.Clin.Invest. 101 2387. PMID: 9616210.
Parmee et al (1998) Discovery of L-755,507: a subnanomolar human β3 adrenergic receptor agonist. Bioorg.Med.Chem.Lett. 8 1107. PMID: 9871717.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for L-755,507 include:
Pinder et al (2015) Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res 43 9379. PMID: 26429972.
Do you know of a great paper that uses L-755,507 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: L-755,507, supplier, potent, selective, β3, beta3, partial, agonists, adrenergic, receptors, adrenoceptors, L755507, CRISPR, Cas9, HDR, NHEJ, homology, directed, repair, nonhomologous, end, joining, Tocris Bioscience, Adrenergic β3 Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Selective, high affinity, non-competitive α1A adrenoceptor antagonist
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands